Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme Article Swipe
Related Concepts
Violeta Razanskaite
,
Marion Bettey
,
Louise Downey
,
Julia L. Wright
,
J Callaghan
,
Miles Rush
,
Simon Whiteoak
,
Sarah Ker
,
Kim Perry
,
Caron Underhill
,
Efrem Eren
,
Iftikar Ahmed
,
Fraser Cummings
·
YOU?
·
· 2017
· Open Access
·
· DOI: https://doi.org/10.1093/ecco-jcc/jjw216
· OA: W2581549770
YOU?
·
· 2017
· Open Access
·
· DOI: https://doi.org/10.1093/ecco-jcc/jjw216
· OA: W2581549770
A managed switching programme from originator infliximab to biosimilar CT-P13 in IBD, using a gain-share agreement, delivers significant cost savings and investment in clinical services while maintaining similar patient-reported outcomes, biochemical response, drug persistence, and adverse event profile.
Related Topics
Finding more related topics…